Prevalence and prognostic value of elevated soluble urokinase plasminogen activator receptor (suPAR) in patients admitted with acute heart failure

BACKGROUND: The inflammatory biomarker, soluble urokinase plasminogen activator receptor (suPAR), has emerged as a promising prognostic biomarker in cardiovascular diseases. However, little is known about suPAR levels in patients admitted with acute heart failure (AHF). This study investigates the prevalence and prognostic value of elevated suPAR in patients hospitalized with AHF. METHODS: This cohort study included patients presenting with cardiopulmonary symptoms at the Medical Emergency Department of University Hospital Amager-Hvidovre, Denmark, between March 10, 2020, and March 31, 2022. SuPAR was measured upon admission, with the median time from admission to measurement of two hours (IQR 3.9 - 6.9). A cardiologist adjudicated whether the patients had AHF. Patients were stratified according to validated cut-off values of suPAR